The field of pathology is rapidly transforming from a semi-quantitative and empirical science toward a Big-Data discipline. Large data-sets from across multiple -omics fields may now be extracted from a patient's tissue sample. Tissue is, however, complex, heterogeneous and prone to artefact. A reductionist view of tissue and disease progression, which does not take this complexity into account, may lead to single biomarkers failing in clinical trials. The integration of standardised multi-omics Big-Data and the retention of valuable information on spatial heterogeneity is imperative to model complex disease mechanisms. Mathematical modelling through systems pathology approaches is the ideal medium to distil the significant information from these large, multi-parametric and hierarchical data-sets. Systems pathology may also predict the dynamical response of disease progression or response to therapy regimens from a static tissue sample. Next generation pathology will incorporate Big-Data with systems medicine in order to personalise clinical practise for both prognostic and predictive patient care.
Introduction
The manual, microscopic viewing of thinly cut and stained tissue sections by histopathologists has been the steadfast method of deciphering tissue architecture and concluding a prognosis for multiple diseases for over one hundred years. The field of pathology recognises the rich data source which lies within a tissue section. With the aid of specific histochemical stains, augmented by immunological and even mRNA or DNA based approaches, the pathologist takes into account the entire heterogeneous and heterotypic microenvironment and its interactions across the tissue section.
Through experience they are able to process this complex, sometimes subtle information, and translate it in order to aid their diagnostic or prognostic conclusion. Research pathologists also apply this methodology to evaluate novel or significant prognostic features such as the tumour differentiation, tumour gland morphology at the invasive front or immune infiltrate within the microenvironment. The development of immunohistochemistry from the 1940s provided the pathologist with the ability to interrogate the tissue section with a further level of complexity where they could match biomarker expression with histopathological features and morphometry, although it took some time and the advent of monoclonal antibodies some 30 years or so later for a dramatic increase in routine use of the technology. The use of protein biomarkers, visualised through immunohistochemistry, allowed quantification at both spatial heterogeneity and subcellular resolution. Since the post-omics era the field of modern pathology is experiencing an explosion of data across multiple but disparate -omics strands. Most notably within the clinic is the genomic profiling of a patient's tissue sample through next generation sequencing (NGS) where, in colorectal cancer for example, EGFR and KRAS mutations now may be routinely tested for in order to predict the response to anti-EGFR antibody treatment. Single "magic-bullet" biomarkers, however, have a limited use in clinical prognosis, drug prediction and efficacy studies as they attempt to describe or modulate complex multi-pathway molecular and cellular interactions in an often too simplistic way.
Advances in the integration of genomics, proteomics, transcriptomics, epigenomics and the emerging field of image analysis based phenomics are now able to add valuable information to the hierarchical understanding of complex disease mechanisms. These molecular signatures correlated with morphological and clinical data have the ability to advance traditional diagnostic medicine from broad population-based prediction to a more personalised and precision based science. Pathology has overcome the bottleneck of creating large, hierarchical and complex "Big-Data", however the challenge the field is now facing is how to handle this data in a meaningful manner which directly leads to translational impact. The over-arching goal of modern big-data pathology is to infer a dynamical prediction of disease from a static patient tissue sample. Systems pathology through mathematical modelling allows the integration, interrogation and identification of significant parameters from large multi-omics data sets while having the ability to add a dynamic aspect to personalised medicine.
Tissue is Heterogeneous
Tissue is extremely heterogeneous and cancer especially so; cancer heterogeneity can originate from multiple sources: cell of origin, clonal evolution, cancer stem cells (CSC), response to microenvironment and host factors as well as stromal or immune cell infiltrate. The clonal evolution theory states that the cancers build up heterogeneous subpopulations after concurrent mutations over multiple rounds of cell division due to the plasticity of the cells through chromosomal and replicative instability or exogenous insults. These heterogeneous subpopulations are under the influence of natural selection where they may acquire mutations which ultimately lead to cell death while others accumulate a specific set of driver mutations allowing the cancer cells to metastasise. CSCs may originate from healthy tissue stem cells or may have attained their stem-like phenotype through epigenetic alterations of the genome or through stromal cell interaction from their microenvironmental niche. The stem-like attributes associated with CSCs would confer a certain amount of plasticity upon it in order for it to evade aggressive treatment regimens or commit to the metastatic cascade. CSCs may have the ability to produce hierarchical heterogeneous cell subpopulation progenies of which only some are tumourigenic and others differentiated. CSCs are thought to initiate tumourigenesis, have the ability to propagate the cancer after chemotherapy and a cure for the patient depends on the eradication of such self-renewing cells. CSCs also appear to be more resistant to radiation and chemotherapeutic treatment and may incur tumour recurrence even after a long period of remission and dormancy. More recently the "Big Bang model" of intra-tumour heterogeneity has been described where tumours mainly grow as a single expansion and that intratumour heterogeneity within tumour subpopulations is high but occurs early on in the tumour's evolution. In this model aggressive subclones may not be predominant and can remain undetected although they would provide overall resistance to subsequent insult by treatment regimens (1).
The focus of cancer research for prognosis, prediction and drug discovery has been on the tumour itself however this target is changing. It is becoming apparent that the tumour microenvironment as a whole, and more precisely the stromal and immune infiltrate, is increasingly important in tumour Automated quantification of the tissue section, spanning the -omics fields, is not able to be so selective and may therefore return variable results. The need for standardisation across all aspects of automated tissue datafication is therefore essential.
Advances in extracting data in a meaningful and robust manner will add value to classical histopathology methodologies and provide greater impact and accuracy of patient stratification at a more personalized level than current population statistics, such as TNM staging. This is increasingly relevant when the quantification techniques take into account the heterogeneity of the disease and report on it. Datafication of tissue is the extraction of information in a fully quantifiable and standardised manner. This can take the form of quantifying a single biomarker to capturing a complex and hierarchical multi-modal omics signature. Routinely, single read-outs are extracted from a single tissue sample however advances in data capturing technologies now allow multiple readouts captured across multiple -omics fields which may be reported across distinct subpopulations identified through morphometric or biomarker expression. Big-data pathology is now a reality but creating standardized data sets amenable to complex modelling and which take into account the imperfection of tissue and its inherent heterogeneity is still in its infancy.
Quantifying heterogeneity
Understanding tumour heterogeneity is important in striving toward an intelligent and individualised treatment strategy which translates into clinical impact. To truly fulfil a personalised medicine approach and select the correct combination therapy for a patient it is essential to know which Inter-patient and intra-patient heterogeneity exists ( Figure 1 ) and the aim of all 'omics' research is to identify biomarkers which can lead to targeted drug discovery programmes or companion diagnostics which will allow the clinician and pathologist to make rapid informed decisions on the prognosis of the disease and to predict which treatment will display the greatest efficacy and best outcome as possible for the individual patient.
Although the above methodologies to quantify the molecular mode of action driving cancer subtypes have added significant value, they also hold disadvantages to assaying such complex material. To extract DNA, RNA and protein molecules these assays usually homogenise and destroy the tissue integrity. The tissue is literally "mashed and measured" mixing together any subpopulations of cancer and host cells expressing differential properties while losing spatial resolution. This results in one end-point being reported for the whole tumour. Due to the nature of these applications, intra-tumoural heterogeneity of the tissue may be under-detected where the dominant or most abundant genotypes or phenotypes mask signal from smaller cell populations within the tumour. Healthy tissue and host cells from the tumour microenvironment are both also added to the molecular sample creating a further source of noise to the signal and could increase the reporting of false positive or negative results.
Under-detection of tissue heterogeneity therefore leads to an urgent and difficult problem when treating a patient with combination therapy, as resistant subgroups could go unnoticed and untreated.
There are, however, tools to overcome this problem which attempt to better quantify, and thus comprehend, the complexity of heterogeneous tumours. One such tool is laser capture microdissection significance of biomarkers and it is becoming increasingly apparent that this must be taken into consideration for the modelling of disease. The immunoscore in colorectal cancer, which quantifies the density and intra-tumoural location of CD3+ and CD8+ lymphocytes through image analysis, has been shown to hold a higher prognostic significance than the gold standard of TNM staging (4) .Similarly, the spatial heterogeneity of unbiased and automatically quantified lymphocytes in breast cancer tissue sections was statistically modelled and found to be associated to patient survival(5). In the field of transcriptomics it has recently been discovered that mesenchymal cell gene expression classifiers are linked to poor prognosis in colorectal cancer though it proves difficult to ascertain whether these classifiers are expressed by the tumour or the stromal cells however Sophisticated data mining is required to identify the significant single or combination of parameters within the signature in order to stratify patients for prognostic or predictive purposes. Data mining techniques previously applied to identify significant parameters have been logistic regression analysis and ensemble decision tree models. Further advancements in in situ labelling and image analysis such as mass spectrometry imaging, Next-generation immunohistochemistry (9) and multi-parametric data capture, where biomarkers are correlated to morphometry, are catapulting this field into the realm of true Big-Data alongside the more traditional -omics fields. Image analysis and in situ labelling of tissue sections coupled to spatial statistics will most probably factor highly when profiling a diseases complex heterogeneous microenvironment in the future of systems pathology.
Integrative pathology
Traditional omics research attempts to identify single molecular or histopathological features which could be utilized for prognosis or prediction of response to drug therapy. Cancer is, however, a very complex disease with multiple molecular interactions within the cell and multiple cellular interactions within the microenvironment. Many single biomarkers never translate to the clinic, as they do not take into account the complexity and heterogeneity of the disease. Integrating large scale data from multiple omics fields may help to address this problem as it will create a better understanding of the multiple molecular interactions occurring within the cell and how these translate to disease progression. This approach was exemplified in colorectal cancer where histopathological subtypes were integrated with methylation and mutation status to assess their correlation and impact on prognosis (10) . Integrative large scale pathology has also been implemented in breast cancer where cellular resolution of in situ and co-registered genotype and phenotype was utilised to study intratumoural heterogeneity between primary and distant metastasis for studies of prognosis and potential drug targets (11) . Finally, a further breast cancer study integrated a multi-omics signature and discovered JAK-STAT and TNF signalling pathways to be significant in triple negative disease which could lead to novel and personalised drug treatments (12) . There is a wealth of data collected during classical histopathology which largely remains unused in clinical decision making. This clinical data is beginning to be integrated with the modern datafication modalities as a further hierarchical level of understanding of the disease from the tissue. In mucoepidermoid carcinoma; histopathology, immunophenotypic and cytogenetic parameters were integrated to identify a signature which was able to identify the pulmonary disease from other subtypes of lung cancer (13) . Clinical and molecular data is now also being integrated with the complex and data-rich image-based phenotypic signatures to investigate cancer heterogeneity and its interaction with the microenvironment. The morphometric signatures can also be correlated to the genomic profile and clinical outcome (5). Computational IT solutions are also now available which allow the incorporation of multiscale omics data (14, 15) as well as integrate it with clinical information (16).
Systems pathology
Pathology is now adept at creating large and complex data sources from across the omics fields and more recently including histopathology, morphometrics and spatial heterogeneity. This data, however, must be integrated in a meaningful way which makes best use of its complexity, is standardized, reproducible and robust enough to be clinically relevant. The challenge ahead is how to incorporate this integrated data into models which can identify the optimal combinations of parameters to answer clinical questions in a robust and standardised manner. Systems medicine, and more recently systems pathology, takes a holistic view of tissue, the cell and its multitude of interactions. Systems pathology requires a large amount of high-quality multi-scale data to be extracted from tissue and which acts as input for predictive mathematical models. Although systems pathology has predominantly concentrated on molecular profiling of the genome, transcriptome or proteome, image analysis based multi-parametric biomarker and morphometry is perfectly matched to add to the hierarchical data within a systems model. This additional in situ information allows the retention of the valuable spatial heterogeneity within the diseases microenvironment.
Essentially, a modern integrative pathology would adopt the principles of 4P medicine in a systems pathology approach. 4P medicine consists of Prediction, Personalisation, Prevention and Patient participation (17) . There are many definitions of systems medicine. Within Europe systems medicine is defined by the EU consortium CASyM (www.casym.eu), as stated within the first chapter of this book.
The principle of systems pathology is to predict a dynamic pathological response from static data sets.
The more standardised and robust the data which is used for input into the model directly relates to the quality of prediction within the model. Systems pathology is complex with the implementation of multiple differential equations into a multiscale dynamic model to predict a drug effect on a patient or inform how that patient will respond over time. Systems pathology, under this definition, was utilised to confirm the role of PTEN in Trastuzumab drug resistance (18) . Systems pathology can also be implemented to track tumour evolution post chemotherapy through intra-tumour heterogeneity and spatial distribution of phenotype and genotype at the cellular level (19) . In CRC a systems pathology approach was employed to identify a disease recurrence signature in early stage patients from a multiomics data set where parameters associated with immune response were found to be the most significant predictors (20).
Systems pathology is therefore already making a valuable impact into the field of translatable clinical research. Systems pathology is the ideal tool to distill significant parameters with significant population cut-offs, and which are therefore translatable to the clinic, from multiple integrated complex Big-Data sets. This is what we have termed 'Next Generation Pathology'. The ultimate goal of next generation pathology is to make use of this hierarchical data captured across multiple modalities from an imperfect and static tissue sample, in order to better understand both disease progression and a patient's personalised response to treatment. 
